Obseva (NASDAQ:OBSV)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Friday. They presently have a $27.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 92.86% from the company’s current price.
The analysts wrote, “EDELWEISS Blooming Next Quarter; Reiterate Buy Stock Data Intraday 03/09/2018 Price $14.00 Exchange NASDAQ Price Target $27.00 52-Week High $15.81 52-Week Low $5.00 Enterprise Value (M) $409.2 Market Cap (M) $520 Public Market Float (M) 13.4 Shares Outstanding (M) 37.1 3 Month Avg Volume 35,780 Short Interest (M) 0.03 Balance Sheet Metrics Cash (M) $110.8 Total Debt (M) $0.0 Total Cash/Share $2.99 Book Value/Share $2.84 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.22) (0.58) (0.45) 2Q — (0.61) (0.44) 3Q (0.30) (0.59) (0.51) 4Q (0.51) (0.48) (0.51) FY (1.40) (2.25) (1.92) 16 14 12 10 8 6 4 MAR- 17 J UL- 17 NOV- 17 MAR- 18 2 1.5 1 0.5 0 Vol. (mil) Price Financial results reported—net loss in-line with forecast. This morning, ObsEva S.A. reported its financial results for the fourth quarter and full-year 2017.””
A number of other brokerages also recently weighed in on OBSV. Zacks Investment Research downgraded shares of Obseva from a “hold” rating to a “sell” rating in a report on Tuesday. BMO Capital Markets reaffirmed a “buy” rating and set a $24.00 price target on shares of Obseva in a report on Tuesday, February 27th. Leerink Swann upped their price target on shares of Obseva from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $18.00 price target (up previously from $16.00) on shares of Obseva in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $20.00.
Obseva (NASDAQ:OBSV) last posted its quarterly earnings data on Friday, March 9th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.08. equities analysts forecast that Obseva will post -2.34 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of OBSV. Sphera Funds Management LTD. lifted its holdings in shares of Obseva by 12.4% during the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock worth $2,118,000 after acquiring an additional 28,700 shares during the period. VHCP Management II LLC lifted its holdings in shares of Obseva by 834.2% during the 3rd quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock worth $11,407,000 after acquiring an additional 1,251,343 shares during the period. Abingworth LLP bought a new stake in shares of Obseva during the 3rd quarter worth approximately $3,480,000. Iguana Healthcare Management LLC increased its position in Obseva by 66.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock worth $407,000 after purchasing an additional 20,000 shares in the last quarter. Finally, First Manhattan Co. acquired a new position in Obseva during the 4th quarter worth approximately $9,760,000. 52.62% of the stock is owned by institutional investors.
Obseva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.